AIM2 and Stroke: We demonstrate that 4-sulfonic calixarenes are effective in vivo at preventing AIM2-dependent post-stroke immunosuppression, providing the foundation for a new therapeutic approach to limit deadly infections after stroke and functioning as a new investigative tool to study dsDNA-dependent inflammatory processes in pre-clinical disease models.